New Delhi: Merck has introduced an advanced drug discovery solution AIDDISON which is a SaaS platform designed to link virtual molecules with manufacturability via integration with the Synthia retrosynthesis solution API. This innovative solution incorporates machine learning (ML), generative AI, and CAD design for drugs to accelerate the drug development process.
AIDDISON has been trained using extensive datasets from over two decades of pharmaceutical R&D. The software has the capability to identify compounds from a pool of more than 60 Bn. possibilities, focusing on key properties essential for successful drugs, including solubility, stability, and non-toxicity. Additionally, the platform offers recommendations for the most effective synthesis methods.
The process of drug discovery is known for its lengthy and iterative nature. The task of selecting the best chemical compound or mixture from a colossal pool of over 1060 molecules demand considerable resources, time, and expertise.
The utilization of AI and ML models such as ‘AIDDISON’ helps reveal hidden insights within an extensive dataset, ultimately enhancing the success rate of bringing newer and better therapies for patients. It is projected that AI could generate savings of over USD 70 billion for drug discovery by 2028, while also reducing the cost and time for the discovery of drugs in pharmaceutical firms by up to 70%.